Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Shares Surge 15.3 Percent On News of Q4 MassArray Placements

NEW YORK, Jan. 5 (GenomeWeb News) - Shares in Sequenom were up 15.3 percent at $1.44 in strong volume in mid-afternoon trade after the company said it has delivered nine MassArray systems during the fourth quarter.

 

The San Diego-based high-throughout-genotyping company said the placements bring to 20 the total systems delivered in 2004. Sequenom added that the recently approved MassArray Compact system helped drive the placements.

Sequenom began selling the compact MassArray in September 2003. The product, which is 73 percent smaller than the full-size system, takes 45 minutes to run a single plate, according to a company spokesperson. The standard MassArray platform takes around 25 minutes.

Another difference is that the compact system holds two chips per plate, whereas the larger one holds 10. With its softer throughput and a price tag of around $285,000 without the liquid handler - the larger instrument runs around $500,000 - the spokesperson, who has since left the company, said the junior platform will be marketed to smaller academic labs and to the clinical-research market.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.